Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Income from Continuing Operations came in at 7384000.0 in Q1 2026, up 46.75% YoY from 5031642.65 in Q1 2025, and down 125.19% on a QoQ basis from 29319000.0 in Q4 2025.
Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Income from Continuing Operations data on file, last reported at 7384000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 46.75% year-over-year to 7384000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 113465000.0 (up 40.58% YoY) and the FY2025 annual result came in at 5165000.0, up 102.71% from the prior year.
- Income from Continuing Operations slipped to 7384000.0 in Q1 2026, from 29319000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 29319000.0 in Q4 2025 to a low of 142664000.0 in Q4 2024.
- A 5-year average of 33492411.76 and a median of 16546000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 120.55% in 2025, down 502.72% in 2025.
- Tracing SPRO's Income from Continuing Operations over 5 years: stood at 92369000.0 in 2022, then jumped by 35.51% to 59567000.0 in 2023, then tumbled by 139.5% to 142664000.0 in 2024, then soared by 120.55% to 29319000.0 in 2025, then sank by 125.19% to 7384000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 7384000.0 (Q1 2026), 29319000.0 (Q4 2025), and 27730000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | -9.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.61 Mn |
| Mar 31, 2026 | -7.38 Mn |
| Dec 31, 2025 | 29.32 Mn |
| Sep 30, 2025 | -27.73 Mn |
| Jun 30, 2025 | -107.67 Mn |
| Mar 31, 2025 | -13.87 Mn |
| Dec 31, 2024 | -142.66 Mn |
| Sep 30, 2024 | -16.55 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -12.66 Mn |
| Dec 31, 2023 | -59.57 Mn |
| Sep 30, 2023 | -3.20 Mn |
| Jun 30, 2023 | -11.91 Mn |
| Mar 31, 2023 | -13.27 Mn |
| Dec 31, 2022 | -92.37 Mn |
| Sep 30, 2022 | -11.84 Mn |
| Jun 30, 2022 | -26.07 Mn |
| Mar 31, 2022 | -34.09 Mn |
| Dec 31, 2021 | -129.95 Mn |
| Sep 30, 2021 | -55.73 Mn |